Antigen presenting cells capture tumour antigen within the tumour microenvironment and migrate to tumour-draining lymph nodes where they prime tumour-reactive T cells. Tumour-reactive T cells then ...
Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...
Toxoplasma gondii is a major global health concern, particularly affecting pregnant women and immunocompromised individuals ...
Trained immunity enhances innate immune responses, yet a Western lifestyle may lead to maladaptive trained immunity and drive non-communicable diseases.
Immunotherapeutic interventions are showing promise in cancer treatment, but challenges like low response rates, off-target delivery, and toxicity still persist. Immunomodulatory nanocomplexes (ImNcs) ...
Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results